Share on StockTwits

Shares of VIVUS (NASDAQ:VVUS) have earned an average rating of “Hold” from the fifteen ratings firms that are covering the company, StockRatingsNetwork reports. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $8.00.

Shares of VIVUS (NASDAQ:VVUS) opened at 5.08 on Friday. VIVUS has a 52-week low of $4.71 and a 52-week high of $15.62. The stock has a 50-day moving average of $5.59 and a 200-day moving average of $7.96. The company’s market cap is $524.8 million.

VIVUS (NASDAQ:VVUS) last issued its quarterly earnings data on Monday, February 24th. The company reported ($0.17) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.40) by $0.23. The company had revenue of $44.06 million for the quarter, compared to the consensus estimate of $28.20 million. On average, analysts predict that VIVUS will post $-1.67 earnings per share for the current fiscal year.

VVUS has been the subject of a number of recent research reports. Analysts at Wells Fargo & Co. initiated coverage on shares of VIVUS in a research note on Thursday. They set a “market perform” rating on the stock. Separately, analysts at Citigroup Inc. cut their price target on shares of VIVUS from $8.00 to $3.00 in a research note on Thursday, April 3rd. They now have an “underweight” rating on the stock. Finally, analysts at Piper Jaffray downgraded shares of VIVUS from a “neutral” rating to an “underweight” rating in a research note on Thursday, April 3rd. They now have a $3.00 price target on the stock, down previously from $8.00.

VIVUS, Inc is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.